NYSE · Healthcare · Diagnostics & Research · USA
Revvity Inc is a large cap company (market value between $10 billion and $200 billion) in the Diagnostics & Research industry.
Revvity supplies health science solutions and services enabling research and clinical care across multiple therapeutic areas. The company operates through Life Sciences, providing reagents, instruments and software for drug discovery and development to pharmaceutical, biotech and academic organizations; and Diagnostics, delivering screening and detection products. The company serves customers worldwide through its portfolio of technologies and expertise.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Revvity Inc stock.
Overvalued: intrinsic value $52.30 per share, market price $156.01, margin of safety -198.3% (as of 2026-10-20).
Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $52.30; the price of $156.01 is 198% above that value, and 73% of that value comes from beyond year five.
Leak Score: 50/100 on 12 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
13 more in this industry show a wider margin of safety.
RVTY is overvalued (as of the 2026-10-20 close). Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $52.30; the price of $156.01 is 198% above that value, and 73% of that value comes from beyond year five.
$52.30 per share (as of the 2026-10-20 close), against a market price of $156.01. That is a margin of safety of -198.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
50 out of 100, which we rate "Weak Signal", on 12 of 12 value investing signals.